Acquisition by Rodgers Richard J of 41143 shares of Ocuphire Pharma subject to Rule 16b-3
OCUPDelisted Stock | USD 1.13 0.06 5.04% |
Slightly above 61% of Ocuphire Pharma's investor base is looking to short. The analysis of current outlook of investing in Ocuphire Pharma suggests that many traders are alarmed regarding Ocuphire Pharma's prospects. Ocuphire Pharma's investing sentiment overview a quick insight into current market opportunities from investing in Ocuphire Pharma. Many technical investors use Ocuphire Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Ocuphire |
Filed transaction by Ocuphire Pharma Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Ocuphire Pharma Fundamental Analysis
We analyze Ocuphire Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocuphire Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocuphire Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Ocuphire Pharma is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Ocuphire Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ocuphire Pharma stock to make a market-neutral strategy. Peer analysis of Ocuphire Pharma could also be used in its relative valuation, which is a method of valuing Ocuphire Pharma by comparing valuation metrics with similar companies.
Peers
Ocuphire Pharma Related Equities
EYEN | Eyenovia | 23.73 | ||||
RNAZ | Transcode Therapeutics | 11.76 | ||||
FBIO | Fortress Biotech | 9.52 | ||||
SLS | Sellas Life | 2.56 | ||||
RIGL | Rigel Pharmaceuticals | 2.34 | ||||
KOD | Kodiak Sciences | 2.02 | ||||
CKPT | Checkpoint Therapeutics | 1.74 | ||||
FBIOP | Fortress Biotech | 0.77 | ||||
PLX | Protalix Biotherapeutics | 1.75 | ||||
CGTX | Cognition Therapeutics | 2.44 | ||||
EYPT | Eyepoint Pharmaceuticals | 2.49 | ||||
RVPH | Reviva Pharmaceuticals | 2.61 | ||||
MBIO | Mustang Bio | 4.76 | ||||
RVPHW | Reviva Pharmaceuticals | 9.52 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Ocuphire Stock
If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |